Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $8.87 Consensus PT from Analysts

Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) has received a consensus rating of "Hold" from the seventeen ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and two have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $8.87.

Several research firms have weighed in on SAGE. Wedbush restated a "neutral" rating and set a $6.00 price target on shares of Sage Therapeutics in a report on Wednesday, February 12th. Scotiabank decreased their price objective on shares of Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating for the company in a research note on Wednesday, February 12th. Canaccord Genuity Group reduced their price target on shares of Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating on the stock in a research note on Wednesday, February 12th. HC Wainwright reiterated a "neutral" rating and issued a $12.00 target price (down from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Finally, Wall Street Zen downgraded shares of Sage Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, June 7th.

Hedge Funds Weigh In On Sage Therapeutics

Large investors have recently made changes to their positions in the company. SG Americas Securities LLC grew its position in Sage Therapeutics by 57.7% during the fourth quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company's stock valued at $122,000 after buying an additional 8,228 shares during the period. Empowered Funds LLC purchased a new stake in shares of Sage Therapeutics during the 4th quarter worth about $91,000. Ieq Capital LLC purchased a new stake in shares of Sage Therapeutics during the 4th quarter worth about $57,000. US Bancorp DE grew its position in shares of Sage Therapeutics by 22.3% during the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company's stock valued at $67,000 after acquiring an additional 2,268 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Sage Therapeutics by 2.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 462,309 shares of the biopharmaceutical company's stock valued at $2,510,000 after acquiring an additional 10,116 shares during the period. 99.22% of the stock is currently owned by institutional investors and hedge funds.

Sage Therapeutics Stock Performance

Shares of NASDAQ SAGE traded down $0.15 during trading on Wednesday, hitting $6.62. The company had a trading volume of 107,864 shares, compared to its average volume of 1,162,163. Sage Therapeutics has a 12 month low of $4.62 and a 12 month high of $13.47. The firm has a market capitalization of $414.55 million, a P/E ratio of -1.00 and a beta of 0.18. The stock has a 50 day simple moving average of $6.96 and a 200 day simple moving average of $6.84.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. The firm had revenue of $14.06 million during the quarter, compared to analysts' expectations of $14.12 million. During the same period in the prior year, the company posted ($1.80) earnings per share. The company's revenue was up 78.0% compared to the same quarter last year. As a group, analysts predict that Sage Therapeutics will post -3.52 EPS for the current year.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.